Top Research Reports for Eli Lilly, Netflix & GE Aerospace
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 14 2025
0mins
Source: NASDAQ.COM
Research Reports on Major Stocks: Zacks Research Daily highlights reports on 16 major stocks, including Eli Lilly, Netflix, and GE Aerospace, showcasing their performance and challenges in the market, particularly focusing on new product demand and competition.
Market Insights and Economic Data: The article emphasizes the importance of the 'Ahead of Wall Street' section for investors, providing insights into economic releases and their potential impact on daily trading actions, alongside a big week of inflation data and Q2 earnings reports.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 883.960
Low
950.00
Averages
1192
High
1500
Current: 883.960
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amazon and OpenAI Strategic Partnership Upgrade
- Microsoft Agreement Revision: The amended agreement between OpenAI and Microsoft allows OpenAI to offer all its products across any cloud provider, which is expected to positively impact Amazon Web Services (AWS), even though Amazon's stock showed little movement on the day after a 26% rise this month.
- Amazon CEO Commentary: Amazon CEO Andy Jassy expressed excitement about OpenAI's announcement on social media platform X, highlighting that the upcoming Stateful Runtime Environment will provide developers with more choices, further enhancing AWS's competitive edge in the market.
- Eli Lilly Acquires Ajax: Eli Lilly announced the acquisition of Ajax Therapeutics for up to $2.3 billion, with Ajax's lead asset being an investigational oral JAK2 inhibitor currently in Phase 1 trials, aimed at expanding Lilly's portfolio beyond GLP-1 drugs.
- Analyst Price Target Adjustment: Leerink maintained Eli Lilly's
See More
Eli Lilly Acquires Ajax Therapeutics for $2.3 Billion
- Acquisition Activity: Eli Lilly accelerates its acquisition strategy in 2026 with the buyout of Ajax Therapeutics valued at up to $2.3 billion, including milestone payments, further solidifying its position in blood cancer treatments.
- Drug Development: Ajax's lead drug, AJ1-11095, is a next-generation JAK2 inhibitor currently in Phase 1 trials for patients with Myelofibrosis, aiming to expand treatment options for patients with rare blood cancers.
- Strategic Positioning: This marks Lilly's sixth acquisition this year, including a $6.3 billion deal for Centessa Pharmaceuticals focused on sleep disorders, demonstrating its commitment to deepening its oncology pipeline.
- Market Sentiment: Despite nearly a 20% decline in LLY shares in 2026, retail sentiment on Stocktwits remains bullish, indicating confidence in the company's acquisition strategy and its potential to enhance future growth.
See More
Pharma Giants Race to Develop Heart Attack Prevention Drugs
- Heart Attack Prevention Drug Development: Novartis, Amgen, and Eli Lilly are conducting late-stage trials to test whether drugs that lower Lp(a) cholesterol levels can effectively prevent heart attacks, with potential annual sales reaching $5.6 billion by 2032 if successful.
- Importance of Clinical Trials: Novartis' pelacarsen has shown over 80% efficacy in reducing Lp(a) levels; however, delays in trial results have raised market concerns about its potential impact, particularly among patients with cardiovascular disease.
- Market Potential and Challenges: Despite the significant market potential for Lp(a) drugs, less than 1% of adults in the U.S. have been tested for Lp(a), and physician reluctance to screen may hinder drug adoption and market acceptance.
- Future Outlook: The results from Novartis' trials will provide direction on the clinical efficacy of Lp(a)-targeting drugs, and if successful, could open a new class of medications to meet the needs of high-risk patients while promoting wider adoption of Lp(a) testing.
See More
Novartis and Others Develop Lp(a) Lowering Drugs
- New Frontier in Heart Disease Prevention: Pharmaceutical giants Novartis, Amgen, and Eli Lilly are conducting late-stage trials to test whether drugs that lower Lp(a) levels can effectively prevent heart attacks, with potential annual sales reaching $5.6 billion by 2032, indicating significant market potential.
- Genetic Determinism: Lp(a) levels are almost entirely genetically determined, with lifestyle factors having limited influence, making drug development crucial for addressing the needs of high Lp(a) patients, particularly as approximately one in five people globally face this issue.
- Importance of Clinical Trials: Novartis's Horizon trial is expected to release results later this year, and if its drug pelacarsen is proven effective in reducing heart attack risk, it will provide critical data support for the entire Lp(a) drug development pipeline, influencing industry confidence.
- Market Acceptance Challenges: Despite rapid drug development, less than 1% of adults in the U.S. were tested for Lp(a) in 2024, reflecting physician hesitance towards screening, indicating that future market acceptance of these drugs will heavily rely on supportive clinical data.
See More
U.S. Stock Futures Decline as Investors Eye Big Tech Earnings
- Market Sentiment: Stock index futures opened lower on Monday as investors remain cautious ahead of the upcoming earnings reports from major tech companies, reflecting concerns about future economic conditions.
- Meta Acquisition Blocked: Meta Platforms (META) was flat before the opening bell after the National Development and Reform Commission of China blocked its planned $2 billion acquisition of AI startup Manus, highlighting the complexities of international mergers and acquisitions.
- Eli Lilly's Acquisition: Eli Lilly (LLY) edged up 0.1% after agreeing to acquire Ajax Therapeutics for up to $2.3 billion in cash, a move that will enhance its presence in blood cancer therapies and potentially drive future growth.
- Verizon's Earnings Report: Verizon Communications (VZ) rose 3.9% ahead of the open, reporting Q1 non-GAAP EPS of $1.28, beating estimates by $0.07, although its revenue of $34.4 billion missed expectations, indicating strong competitive positioning despite challenges.
See More
Chaos Erupts at White House Correspondents' Dinner Amid Security Incident
- White House Chaos: An armed man charged a security checkpoint during the White House Correspondents' Dinner, prompting evacuation of President Trump and officials, which has drawn widespread condemnation and highlights increasing political violence in the U.S.
- Investigation Closure: The Justice Department has ended its criminal investigation into Fed Chair Jerome Powell, clearing the way for Trump's nominee Kevin Warsh, which could significantly influence future monetary policy decisions.
- Iran Negotiation Halt: Trump canceled plans to send U.S. representatives to Pakistan for ceasefire talks, resulting in Brent crude prices surpassing $106 per barrel, exerting downward pressure on stock futures amid faltering peace talks.
- Tesla AI Testing: Tesla is beta testing xAI's Grok chatbot for in-vehicle voice commands, aiming to enhance driver experience, but safety experts warn that such features could distract drivers and compromise road safety.
See More
Amazon and OpenAI Strategic Partnership Upgrade
- Microsoft Agreement Revision: The amended agreement between OpenAI and Microsoft allows OpenAI to offer all its products across any cloud provider, which is expected to positively impact Amazon Web Services (AWS), even though Amazon's stock showed little movement on the day after a 26% rise this month.
- Amazon CEO Commentary: Amazon CEO Andy Jassy expressed excitement about OpenAI's announcement on social media platform X, highlighting that the upcoming Stateful Runtime Environment will provide developers with more choices, further enhancing AWS's competitive edge in the market.
- Eli Lilly Acquires Ajax: Eli Lilly announced the acquisition of Ajax Therapeutics for up to $2.3 billion, with Ajax's lead asset being an investigational oral JAK2 inhibitor currently in Phase 1 trials, aimed at expanding Lilly's portfolio beyond GLP-1 drugs.
- Analyst Price Target Adjustment: Leerink maintained Eli Lilly's
See More
Eli Lilly Acquires Ajax Therapeutics for $2.3 Billion
- Acquisition Activity: Eli Lilly accelerates its acquisition strategy in 2026 with the buyout of Ajax Therapeutics valued at up to $2.3 billion, including milestone payments, further solidifying its position in blood cancer treatments.
- Drug Development: Ajax's lead drug, AJ1-11095, is a next-generation JAK2 inhibitor currently in Phase 1 trials for patients with Myelofibrosis, aiming to expand treatment options for patients with rare blood cancers.
- Strategic Positioning: This marks Lilly's sixth acquisition this year, including a $6.3 billion deal for Centessa Pharmaceuticals focused on sleep disorders, demonstrating its commitment to deepening its oncology pipeline.
- Market Sentiment: Despite nearly a 20% decline in LLY shares in 2026, retail sentiment on Stocktwits remains bullish, indicating confidence in the company's acquisition strategy and its potential to enhance future growth.
See More
Pharma Giants Race to Develop Heart Attack Prevention Drugs
- Heart Attack Prevention Drug Development: Novartis, Amgen, and Eli Lilly are conducting late-stage trials to test whether drugs that lower Lp(a) cholesterol levels can effectively prevent heart attacks, with potential annual sales reaching $5.6 billion by 2032 if successful.
- Importance of Clinical Trials: Novartis' pelacarsen has shown over 80% efficacy in reducing Lp(a) levels; however, delays in trial results have raised market concerns about its potential impact, particularly among patients with cardiovascular disease.
- Market Potential and Challenges: Despite the significant market potential for Lp(a) drugs, less than 1% of adults in the U.S. have been tested for Lp(a), and physician reluctance to screen may hinder drug adoption and market acceptance.
- Future Outlook: The results from Novartis' trials will provide direction on the clinical efficacy of Lp(a)-targeting drugs, and if successful, could open a new class of medications to meet the needs of high-risk patients while promoting wider adoption of Lp(a) testing.
See More
Novartis and Others Develop Lp(a) Lowering Drugs
- New Frontier in Heart Disease Prevention: Pharmaceutical giants Novartis, Amgen, and Eli Lilly are conducting late-stage trials to test whether drugs that lower Lp(a) levels can effectively prevent heart attacks, with potential annual sales reaching $5.6 billion by 2032, indicating significant market potential.
- Genetic Determinism: Lp(a) levels are almost entirely genetically determined, with lifestyle factors having limited influence, making drug development crucial for addressing the needs of high Lp(a) patients, particularly as approximately one in five people globally face this issue.
- Importance of Clinical Trials: Novartis's Horizon trial is expected to release results later this year, and if its drug pelacarsen is proven effective in reducing heart attack risk, it will provide critical data support for the entire Lp(a) drug development pipeline, influencing industry confidence.
- Market Acceptance Challenges: Despite rapid drug development, less than 1% of adults in the U.S. were tested for Lp(a) in 2024, reflecting physician hesitance towards screening, indicating that future market acceptance of these drugs will heavily rely on supportive clinical data.
See More
U.S. Stock Futures Decline as Investors Eye Big Tech Earnings
- Market Sentiment: Stock index futures opened lower on Monday as investors remain cautious ahead of the upcoming earnings reports from major tech companies, reflecting concerns about future economic conditions.
- Meta Acquisition Blocked: Meta Platforms (META) was flat before the opening bell after the National Development and Reform Commission of China blocked its planned $2 billion acquisition of AI startup Manus, highlighting the complexities of international mergers and acquisitions.
- Eli Lilly's Acquisition: Eli Lilly (LLY) edged up 0.1% after agreeing to acquire Ajax Therapeutics for up to $2.3 billion in cash, a move that will enhance its presence in blood cancer therapies and potentially drive future growth.
- Verizon's Earnings Report: Verizon Communications (VZ) rose 3.9% ahead of the open, reporting Q1 non-GAAP EPS of $1.28, beating estimates by $0.07, although its revenue of $34.4 billion missed expectations, indicating strong competitive positioning despite challenges.
See More
Chaos Erupts at White House Correspondents' Dinner Amid Security Incident
- White House Chaos: An armed man charged a security checkpoint during the White House Correspondents' Dinner, prompting evacuation of President Trump and officials, which has drawn widespread condemnation and highlights increasing political violence in the U.S.
- Investigation Closure: The Justice Department has ended its criminal investigation into Fed Chair Jerome Powell, clearing the way for Trump's nominee Kevin Warsh, which could significantly influence future monetary policy decisions.
- Iran Negotiation Halt: Trump canceled plans to send U.S. representatives to Pakistan for ceasefire talks, resulting in Brent crude prices surpassing $106 per barrel, exerting downward pressure on stock futures amid faltering peace talks.
- Tesla AI Testing: Tesla is beta testing xAI's Grok chatbot for in-vehicle voice commands, aiming to enhance driver experience, but safety experts warn that such features could distract drivers and compromise road safety.
See More
